Fennec Pharmaceuticals Inc. earnings releases FENC

Annual Quarterly

Fennec Pharmaceuticals Inc. last reported quarterly results on Mar 10, 2025, for Q4 FY2024 (the quarter ended Dec 31, 2024): revenue of $7.9 million (-18.6% year over year) and diluted EPS of -$0.08. It usually reports 35–69 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–69 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Mar 10, 2025 69 days after quarter end	Q4 FY2024 ended Dec 31, 2024	8 -18.6%	-2 +26.0%	-0.08
Nov 7, 2023 38 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 4, 2023 35 days after quarter end	— ended Jun 30, 2023	—	—	—
Feb 14, 2020 45 days after quarter end	— ended Dec 31, 2019	—	—	—
Nov 12, 2019 43 days after quarter end	— ended Sep 30, 2019	—	—	—
Aug 9, 2019 40 days after quarter end	— ended Jun 30, 2019	—	—	—
May 9, 2019 39 days after quarter end	— ended Mar 31, 2019	—	—	—
Mar 14, 2019 73 days after quarter end	— ended Dec 31, 2018	—	—	—

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: FENC (Nasdaq)
Fiscal year ends: December 31
Incorporated in: British Columbia, Canada
Headquarters: Research Triangle Park, NC
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1211583
Former names: ADHEREX TECHNOLOGIES INC (until Aug 14, 2014)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.